Online inquiry

IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12315MR)

This product GTTS-WQ12315MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ12315MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8297MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ14087MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ11821MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-4280
GTTS-WQ11710MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ13254MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ8511MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Hu3F8
GTTS-WQ5793MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ11931MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MLN2045
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW